{"transactions":[{"id":916842,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-06T21:30:29.000Z","date":"2026-02-04","kind":"sale","planned":false,"acquired":false,"shares":1655,"price":4.52,"value":7480.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."}],"balance_after":1442131,"source":{"system":"sec-edgar","filing":"0001793412-26-000012","document":"form4-02062026_040223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000012/form4-02062026_040223.xml","form_type":"4"}},{"id":930575,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:05.000Z","date":"2026-01-26","kind":"sale","planned":false,"acquired":false,"shares":23849,"price":4.61,"value":109943.89,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive."}],"balance_after":1443786,"source":{"system":"sec-edgar","filing":"0001793412-26-000008","document":"form4-01272026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000008/form4-01272026_040101.xml","form_type":"4"}},{"id":930574,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:05.000Z","date":"2026-01-23","kind":"sale","planned":false,"acquired":false,"shares":78968,"price":4.75,"value":375098.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":1467635,"source":{"system":"sec-edgar","filing":"0001793412-26-000008","document":"form4-01272026_040101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000008/form4-01272026_040101.xml","form_type":"4"}},{"id":939690,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-01-14T21:45:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":231000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":231000,"derivative":{"exercise_price":4.86,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":231000},"source":{"system":"sec-edgar","filing":"0001793412-26-000002","document":"form4-01142026_040105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000002/form4-01142026_040105.xml","form_type":"4"}},{"id":939689,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-01-14T21:45:10.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":359000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1546603,"source":{"system":"sec-edgar","filing":"0001793412-26-000002","document":"form4-01142026_040105.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000179341226000002/form4-01142026_040105.xml","form_type":"4"}},{"id":1058791,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-22T20:15:08.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":54491,"price":2.85,"value":155299.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.841 to $2.865 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1187603,"source":{"system":"sec-edgar","filing":"0001415889-25-022749","document":"form4-08222025_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925022749/form4-08222025_040804.xml","form_type":"4"}},{"id":1174422,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-04-10T20:15:13.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":12462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was awarded on February 2, 2023 by the Compensation Committee (the \"Compensation Committee\") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The shares underlying the option covered by this report vested upon certification. This option was inadvertently omitted for the original Form 4."}],"balance_after":12462,"derivative":{"exercise_price":1.18,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":12462},"source":{"system":"sec-edgar","filing":"0001415889-25-010539","document":"form4a-04102025_040408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925010539/form4a-04102025_040408.xml","form_type":"4/A","original_submission_date":"2023-06-02"}},{"id":1208609,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-03-13T20:15:05.000Z","date":"2025-03-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":29843,"price":1.69,"value":50434.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting and settlement of restricted stock units and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":1242094,"source":{"system":"sec-edgar","filing":"0001415889-25-007997","document":"form4-03132025_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925007997/form4-03132025_040301.xml","form_type":"4"}},{"id":1317453,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-03T22:31:21.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":431000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2026 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":431000,"derivative":{"exercise_price":1.85,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":431000},"source":{"system":"sec-edgar","filing":"0001415889-25-000595","document":"form4-01032025_100118.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000595/form4-01032025_100118.xml","form_type":"4"}},{"id":1317452,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-03T22:31:21.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":431000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSU grant was approved by the Issuer's compensation committee of the board of directors and will be effective as of the date the Issuer has an effective Registration Statement on Form S-8 registering the shares available for issuance under the 2020 Stock Incentive Plan. The RSUs will vest in four equal annual installments beginning on January 2, 2026, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":1271937,"source":{"system":"sec-edgar","filing":"0001415889-25-000595","document":"form4-01032025_100118.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588925000595/form4-01032025_100118.xml","form_type":"4"}},{"id":1657583,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-06T21:42:03.000Z","date":"2024-02-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":1288,"price":1.51,"value":1944.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld by the Issuer to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary transaction by the Reporting Person."}],"balance_after":840937,"source":{"system":"sec-edgar","filing":"0001415889-24-002809","document":"form4-02062024_090255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000141588924002809/form4-02062024_090255.xml","form_type":"4"}},{"id":1689765,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-01-04T21:43:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":590413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 2, 2025 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":590413,"derivative":{"exercise_price":1.71,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":590413},"source":{"system":"sec-edgar","filing":"0001209191-24-000811","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000811/doc4.xml","form_type":"4"}},{"id":1689764,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-04T21:43:04.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":590413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award.  The RSUs will vest in four equal annual installments beginning on January 2, 2025, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":842225,"source":{"system":"sec-edgar","filing":"0001209191-24-000811","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919124000811/doc4.xml","form_type":"4"}},{"id":1708251,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-12-18T21:50:32.000Z","date":"2023-12-14","kind":"grant","planned":false,"acquired":true,"shares":187582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":187582,"derivative":{"exercise_price":0.6989,"expiration_date":"2033-12-14","underlying":"Common Stock","underlying_shares":187582},"source":{"system":"sec-edgar","filing":"0001209191-23-058977","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123058977/doc4.xml","form_type":"4"}},{"id":1797146,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-25T20:30:47.000Z","date":"2023-08-24","kind":"sale","planned":true,"acquired":false,"shares":33000,"price":2.33,"value":76890.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a mandatory \"sell to cover\" arrangement adopted by the Reporting Person on May 26, 2023 in accordance with Rule 10b5-1 to satisfy the tax withholding obligations triggered by the vesting of restricted stock units and does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.185 to $2.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":258042,"source":{"system":"sec-edgar","filing":"0001209191-23-047323","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123047323/doc4.xml","form_type":"4"}},{"id":1871191,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-02T20:12:47.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":6230,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a performance restricted stock unit (\"PRSU\") award. The PRSUs were awarded on February 2, 2023 by the Compensation Committee (the \"Compensation Committee\") of the Issuer's Board of Directors as annual incentive compensation for 2022 performance. On May 31, 2023, the Compensation Committee certified the achievement of a certain performance goal. The PRSUs covered by this report vested upon certification."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each PRSU represented a contingent right to receive one share the Issuer's common stock."}],"balance_after":291042,"source":{"system":"sec-edgar","filing":"0001209191-23-033681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123033681/doc4.xml","form_type":"4"}},{"id":2031317,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-07T02:12:21.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":149900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":149900,"derivative":{"exercise_price":1.18,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":149900},"source":{"system":"sec-edgar","filing":"0001209191-23-007396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123007396/doc4.xml","form_type":"4"}},{"id":2031316,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-07T02:12:21.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":37384,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":37384,"derivative":{"exercise_price":1.18,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":37384},"source":{"system":"sec-edgar","filing":"0001209191-23-007396","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123007396/doc4.xml","form_type":"4"}},{"id":2031315,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-02-07T02:12:21.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":18691,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share the Issuer's common stock."}],"balance_after":284812,"source":{"system":"sec-edgar","filing":"0001209191-23-007396","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919123007396/doc4.xml","form_type":"4"}},{"id":2175533,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-24T20:47:01.000Z","date":"2022-08-23","kind":"sale","acquired":false,"shares":3325,"price":3.47,"value":11537.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.58 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2)."}],"balance_after":266121,"source":{"system":"sec-edgar","filing":"0001209191-22-047353","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122047353/doc4.xml","form_type":"4"}},{"id":2177474,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-23T00:05:59.000Z","date":"2022-08-22","kind":"sale","acquired":false,"shares":9717,"price":3.5,"value":34009.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.71 inclusive."}],"balance_after":269446,"source":{"system":"sec-edgar","filing":"0001209191-22-047097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122047097/doc4.xml","form_type":"4"}},{"id":2177473,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-23T00:05:59.000Z","date":"2022-08-19","kind":"sale","acquired":false,"shares":11482,"price":3.75,"value":43057.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.85 inclusive."}],"balance_after":279163,"source":{"system":"sec-edgar","filing":"0001209191-22-047097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122047097/doc4.xml","form_type":"4"}},{"id":2177472,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-08-23T00:05:59.000Z","date":"2022-08-18","kind":"sale","acquired":false,"shares":7476,"price":3.87,"value":28932.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $3.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4)."}],"balance_after":290645,"source":{"system":"sec-edgar","filing":"0001209191-22-047097","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122047097/doc4.xml","form_type":"4"}},{"id":2300773,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-08T20:27:44.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on April 6, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":6.52,"expiration_date":"2032-04-06","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-023863","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122023863/doc4.xml","form_type":"4"}},{"id":2373346,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-25T21:18:19.000Z","date":"2022-02-23","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":80000,"derivative":{"exercise_price":5.96,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001209191-22-013160","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919122013160/doc4.xml","form_type":"4"}},{"id":2595518,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T21:52:14.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":2094,"price":17.14,"value":35891.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.25 inclusive."}],"balance_after":298121,"source":{"system":"sec-edgar","filing":"0001209191-21-052824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121052824/doc4.xml","form_type":"4"}},{"id":2595517,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T21:52:14.000Z","date":"2021-08-20","kind":"sale","acquired":false,"shares":9746,"price":16.7,"value":162758.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02 inclusive."}],"balance_after":300215,"source":{"system":"sec-edgar","filing":"0001209191-21-052824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121052824/doc4.xml","form_type":"4"}},{"id":2595516,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T21:52:14.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":613,"price":17.11,"value":10488.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.04 to $17.12 inclusive."}],"balance_after":309961,"source":{"system":"sec-edgar","filing":"0001209191-21-052824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121052824/doc4.xml","form_type":"4"}},{"id":2595515,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T21:52:14.000Z","date":"2021-08-19","kind":"sale","acquired":false,"shares":9354,"price":16.43,"value":153686.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.04 to $17.03 inclusive."}],"balance_after":310574,"source":{"system":"sec-edgar","filing":"0001209191-21-052824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121052824/doc4.xml","form_type":"4"}},{"id":2595514,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-20T21:52:14.000Z","date":"2021-08-18","kind":"sale","acquired":false,"shares":11193,"price":17.35,"value":194198.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a \"sell to cover\" transaction pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.95 to\n$17.825 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6)."}],"balance_after":319928,"source":{"system":"sec-edgar","filing":"0001209191-21-052824","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121052824/doc4.xml","form_type":"4"}},{"id":2903490,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-21T01:20:28.000Z","date":"2021-01-19","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the option shall vest and become exercisable on January 19, 2022 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":31,"expiration_date":"2031-01-19","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-21-004571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919121004571/doc4.xml","form_type":"4"}},{"id":3022669,"issuer":{"id":4549,"kind":"organization","name":"Taysha Gene Therapies, Inc."},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-25T21:08:31.000Z","date":"2020-09-23","kind":"grant","acquired":true,"shares":331121,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the RSU vest in 4 equal annual installments on each of August 17, 2021, August 17, 2022, August 17, 2023 and August 17, 2024, subject to the Reporting Person's continuous service as of each such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share the Issuer's common stock."}],"balance_after":331121,"source":{"system":"sec-edgar","filing":"0001209191-20-052110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806310/000120919120052110/doc4.xml","form_type":"4"}},{"id":3281872,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Finance & PFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-10T22:05:26.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 3,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":3000,"derivative":{"exercise_price":23.89,"expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-20-008006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000120919120008006/doc4.xml","form_type":"4"}},{"id":3281871,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Finance & PFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-10T22:05:26.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 25,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":25000,"derivative":{"exercise_price":22.72,"expiration_date":"2030-02-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-008006","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000120919120008006/doc4.xml","form_type":"4"}},{"id":3378591,"issuer":{"id":5627,"kind":"organization","name":"ROCKET PHARMACEUTICALS, INC.","symbol":"RCKT"},"owners":[{"id":67484,"kind":"person","name":"Alam Kamran","position":1,"cik":"0001793412","reported_name":"Alam Kamran","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP - Finance & PFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-06T22:05:19.000Z","date":"2019-11-04","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 1/3 of which will become fully vested and exercisable on November 4, 2020, with the remaining 2/3 vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer."}],"balance_after":200000,"derivative":{"exercise_price":14.25,"expiration_date":"2029-11-04","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-055529","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1281895/000120919119055529/doc4.xml","form_type":"4"}}]}